The Role of Therapeutic Plasma Exchange in Treating Hypertriglyceridemia‐Associated Acute Pancreatitis: A Real‐World Effectiveness Analysis Using the TriNetX Global Collaborative Network
Journal of Clinical Apheresis · 2025-08 · 40 (4)
DOI: 10.1002/jca.70053 ↗At a glance
Journal article in Journal of Clinical Apheresis, published online on 2025-08-27. Written by Nisar Amin and 5 co-authors. Institution: Clinical Assistant Professor, Department of Internal Medicine, Charleston Area Medical Center, Charleston, USA. Major MEDLINE topics: Plasma Exchange, Hypertriglyceridemia, Pancreatitis. Cited 9 times so far (Crossref); 37 references.
Abstract (original language)
Therapeutic plasma exchange (TPE) is used to lower triglyceride levels in patients with severe hypertriglyceridemia‐associated acute pancreatitis (HTG‐AP). However, evidence supporting the effectiveness of TPE in preventing end‐organ damage remains limited. This retrospective cohort study was conducted using the TriNetX database to evaluate adults with acute pancreatitis, triglyceride levels > 1000 mg/dL, and “worrisome criteria”, defined as clinical indicators of disease severity such as fever, leukocytosis, elevated lactate, or signs of shock. Patients receiving TPE within 3 days of diagnosis were compared with patients with no TPE within 30 days. Outcomes included triglyceride reduction to < 500 mg/dL, ICU admission, end‐organ damage, and mortality. Of 14 188 patients with HTG‐AP, 3% ( n = 419) received TPE; 97% ( n = 13 237) were treated without TPE. After 1:1 propensity‐score matching, 2 well‐matched, 412‐patient cohorts were created. More patients in the TPE cohort had a reduction in triglyceride levels to < 500 mg/dL at 1 week (81% vs. 40%, p < 0.001) and 1 month (86% vs. 48%, p < 0.001). However, the TPE cohort also had higher ICU admission rates (39% vs. 19%, p < 0.001). No significant differences in organ failure rates were observed at 1 week (4.4% vs. 3.3%, p = 0.47) or 1 month (5.8% vs. 5.0%, p = 0.71). Similarly, 30‐day (4.4% vs. 6.3%, p = 0.21) and 3‐month (5.3% vs. 7.8%, p = 0.16) all‐cause mortality were comparable between the cohorts. In patients with HTG‐AP, use of TPE within 3 days of diagnosis reduces triglyceride levels effectively but does not significantly reduce the risk of end‐organ damage or mortality. TPE is associated with increased ICU care requirements, which may reflect protocolized ICU admission.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Clinical Assistant Professor, Department of Internal Medicine, Charleston Area Medical Center, Charleston, USA.
- Assistant Professor, Department of Pathology, The University of Chicago, Chicago, USA.
- Assistant Professor, Department of Gastroenterology and Hepatology, West Virginia University, Charleston, USA.
- Assistant Professor, Department of Hematology Oncology, Charleston Area Medical Center, Charleston, USA.
- Professor, Department of Pathology, Medical College of Wisconsin, Milwaukee, USA.
Cite
APA
Amin, N., Carll, T., Chela, H., Kamran, A., Wool, G. D., & Daglilar, E. (2025). The Role of Therapeutic Plasma Exchange in Treating Hypertriglyceridemia‐Associated Acute Pancreatitis: A Real‐World Effectiveness Analysis Using the TriNetX Global Collaborative Network. Journal of Clinical Apheresis, 40(4). https://doi.org/10.1002/jca.70053
Vancouver
Amin N, Carll T, Chela H, Kamran A, Wool GD, Daglilar E. The Role of Therapeutic Plasma Exchange in Treating Hypertriglyceridemia‐Associated Acute Pancreatitis: A Real‐World Effectiveness Analysis Using the TriNetX Global Collaborative Network. Journal of Clinical Apheresis. 2025;40(4). doi:10.1002/jca.70053
BibTeX
@article{Amin2025,
author = {Amin, Nisar and Carll, Tim and Chela, Harleen and Kamran, Amir and Wool, Geoffrey D and Daglilar, Ebubekir},
title = {The Role of Therapeutic Plasma Exchange in Treating Hypertriglyceridemia‐Associated Acute Pancreatitis: A Real‐World Effectiveness Analysis Using the TriNetX Global Collaborative Network},
journal = {Journal of Clinical Apheresis},
year = {2025},
volume = {40},
number = {4},
doi = {10.1002/jca.70053}
}
EUVIMED